Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15

doi:10.1016/j.vaccine.2017.03.042

Vaccine

Volume 35, Issue 18, 25 April 2017, Pages 2372-2378

https://doi.org/10.1016/j.vaccine.2017.03.042 Get rights and content

Highlights

•
Coverage varied up to 16% by ethnic group (adjusted for deprivation and geography).
•
Vaccine coverage was lowest among Mixed: White & Black African ethnic group.
•
Vaccine coverage decreases with increasing deprivation.
•
Ethnicity and deprivation do not wholly account for geographical coverage variation.

Abstract

Introduction

In September 2013, England introduced a shingles vaccination programme to reduce incidence and severity of shingles in the elderly. This study aims to assess variation in vaccine coverage with regards to selected sociodemographic factors to inform activities for improving equity of the programme.

Methods

Eligible 70 year-olds were identified from a national vaccine coverage dataset in 2014/15 that includes 95% of GPs in England. NHS England Local Team (LT) and index of multiple deprivation (IMD) scores were assigned to patients based on GP-postcode. Vaccine coverage (%) with 95% confidence intervals (CIs), were calculated overall and by LT, ethnicity and IMD, using binomial regression.

Results

Of 502,058 eligible adults, 178,808 (35.6%) had ethnicity recorded. Crude vaccine coverage was 59.5% (95%CI: 59.3–59.7). Coverage was lowest in London (49.6% coverage, 95%CI: 49.0–50.2), and compared to this coverage was significantly higher in all other LTs (+6.3 to +10.4, p < 0.001) after adjusting for ethnicity and IMD. Coverage decreased with increasing deprivation and was 8.2% lower in the most deprived (95%CI: 7.3–9.1) compared with the least deprived IMD quintile (64.1% coverage, 95%CI: 63.6–64.6), after adjustment for ethnicity and LT. Compared with White-British (60.7% coverage, 95%CI: 60.5–61.0), other ethnic groups had between 4.0% (Indian) and 21.8% (Mixed: White and Black African) lower coverage. After adjusting for IMD and LT, significantly lower coverage by ethnicity persisted in all groups, except in Mixed: Other, Indian and Bangladeshi compared with White-British.

Conclusions

After taking geography and deprivation into account, shingles vaccine coverage varied by ethnicity. White-British, Indian and Bangladeshi groups had highest coverage; Mixed: White and Black African, and Black-other ethnicities had the lowest. Patients' ethnicity and IMD are predictors of coverage which contribute to, but do not wholly account for, geographical variation coverage. Interventions to address service-related, sociodemographic and ethnic inequalities in shingles vaccine coverage are required.

Introduction

Varicella zoster virus (VZV) causes two distinct diseases. Varicella (chickenpox) is the primary infection and herpes zoster (HZ) or shingles is a reactivation of VZV which occurs due to a decline in cell mediated immunity. Shingles is a painful clinical condition characterised by a unilateral vesicular rash which can occur anywhere on the body but most commonly occurs on the trunk [1]. Post herpetic neuralgia (PHN) is the most frequent complication of shingles which causes persistent neuropathic pain. This debilitating condition extends beyond the resolution of rash, between three and six months on average and is known to contribute significantly to the overall burden of shingles within the population [2], [3], [4].

Shingles incidence in the UK has been estimated at 5.23/1000 person years based on primary care consultations [3], with a lifetime risk estimated between 25% and 35% [5], [6], [7]. Studies have reported between 2.6% and 67.3% of shingles cases develop PHN [8]. Factors that increase risk of both shingles and PHN include increasing age, female gender and immunosuppression either due to treatment or underlying conditions such as HIV and malignancy [2], [3], [9], [10], [11].

In September 2013, following a recommendation from the Joint Committee on Vaccination and Immunisation [12], [13] the UK introduced a shingles vaccination programme to individuals aged 70 years old, with a phased catch-up programme for those aged 71–79 years. The programme is delivered in general practice and operates between September and August each year. Patients are eligible throughout the year, although many receive it at the same time as their annual influenza vaccine. The aim of the vaccination programme is to reduce the incidence and severity of shingles in those targeted by the programme by boosting individuals’ pre-existing VZV immunity through vaccination with a single dose of a live attenuated vaccine (Zostavax).

In the first year of the programme (2013/14), overall coverage in England for the routine cohort was 61.8% [14]. Whilst this demonstrates effective implementation of the programme, equitable delivery, a key requirement of the national immunisation programme outlined in the NHS Public Health Functions Agreement (Section 7A) [15] under the Equality Act, 2010, had not been assessed [16].

Variation in shingles vaccine coverage by ethnicity, age and gender is documented in other high-income countries [17], [18]. Such variation has been attributed to differences in service factors (such as access and utilisation of healthcare and recommendation by the GP or midwife), individual factors (such as knowledge, attitudes and practice with respect to immunisation), sociodemographic factors (such as educational attainment and household income) and other factors including rurality.

In the UK, a number of studies have explored variation in vaccine coverage for other national vaccination programmes including childhood programmes, seasonal influenza and maternal programmes [19], [20], [21], [22], [23], [24], [25], [26], [27], [28]. Although routine shingles coverage data suggest differential coverage among different ethnic groups [14], no similar studies have been undertaken for the shingles immunisation programme in England, and the extent to which differential coverage by ethnicity is due to other, confounding factors such as deprivation or geography, is unknown.

The aims of this study are to:

•
Assess the variation in shingles vaccine coverage across England in 70 year-olds in 2014/15 by key individual and population level factors – ethnicity, deprivation and geography.
•
Identify predictors of shingles vaccine coverage to ascertain if inequalities persist after adjusting for other factors.

Section snippets

Data collection

Eligible and vaccinated 70 year-olds between 1 September 2014 and 31 August 2015 were extracted from GP records. The dataset was generated through the automated upload of aggregated GP practice level shingles vaccine coverage data to ImmForm, a system used by Public Health England (PHE) to monitor vaccine coverage data for new vaccine programmes and programmes targeting those over five years old [29]. ImmForm captures data from approximately 95% of GP practices in England. Eligible individuals

Participation

Of 7802 GP practices in England, shingles coverage data were available for 7473 (95.8%) practices with 502,058 registered patients for the period 1 September 2014 to 31 August 2015. Of these, 262,667 (52.3%) patients were registered at 3977 GP practices where the information system was able to provide ethnicity; 178,808 (35.6%) had ethnicity recorded and 83,859 (16.7%) had unknown ethnicity (i.e. recorded as ‘not stated’, ‘not recorded’ or ‘not given’).

Sample representativeness and overall coverage

The GP practices providing ethnicity were

Main findings

When compared to the White-British group, shingles vaccine coverage was lower in all other ethnic groups and for most of these groups, differences in coverage persisted after adjusting for IMD and LT. Coverage differences by ethnic group have also been reported for other immunisation programmes in England with studies for childhood influenza, HPV and rotavirus immunisation also reporting lower vaccine coverage in non-white ethnic groups [21], [23], [28]. In contrast, a study looking

Conclusions

This study has demonstrated that it is possible to monitor shingles vaccine coverage by ethnic group and identify groups with low recorded coverage using aggregated, routinely collected GP practice data. To strengthen our ability to use routine data to inform public health action and reduce inequalities, we recommend improved recording of coverage and sociodemographic data in GP IT systems. This will help in the delivery of equitable vaccination programmes, as mandated by the Equalities Act [16]

Funding

This work was conducted as part of routine activities at the department of Immunisation, Hepatitis and Blood Safety, Public Health England and received no specific funding.

Conflicts of interest

None.

Contributions

CW, ME and LB were involved in the conception and design of the study. CW, ME, LB and JW were involved in the acquisition of data. All authors made substantial contribution to the interpretation of data, critically revising the article for important intellectual content and final approval of the version to be submitted.

Acknowledgements

The authors would like to acknowledge all staff in PHE and NHS England responsible for the planning and delivery of the shingles immunisation programme. We thank the ImmForm team for their management of the GP sentinel data collections.

References (46)

A. Gater
Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
BMC Infect Dis
(2014)
A.J. Van Hoek
Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales
Vaccine
(2009)
A. Gauthier
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
Epidemiol Infect
(2009)
M.N. Oxman
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
N Engl J Med
(2005)
D. Bowsher
The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population
Eur J Pain
(1999)
M. Brisson
Modelling the impact of immunization on the epidemiology of varicella zoster virus
Epidemiol Infect
(2000)
E. Miller et al.
Epidemiology, outcome and control of varicella-zoster infection
Rev Med Microbiol
(1993)
H.J. Forbes
A systematic review and meta-analysis of risk factors for postherpetic neuralgia
Pain
(2016)
B.F. Jung
Risk factors for postherpetic neuralgia in patients with herpes zoster
Neurology
(2004)
H.F. Tseng
Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease
Jama
(2011)

Government of Alberta. Health Information Act: Health Information Regulation (Alberta Regulation 70/2001 with...

Joint Committee on Vaccination and Immunisation

Statement on varicella and herpes zoster vaccines

(March 2010)

Public Health England. Herpes zoster (shingles) vaccination programme to protect the elderly. HPR 7(35): News, 30...

Public Health England. Herpes zoster (shingles) immunisation programme 2013/2014: Report for England; 2014...

NHS England. Public Health Section 7A Commissioning Intentions, 2015/16; 2015...

Legislation.gov.uk, Equality Act 2010;...

R.C. Hechter

Trends and disparity in zoster vaccine uptake in a managed care population

Vaccine

(2013)

X.C. Liu

Herpes zoster vaccine (HZV): utilization and coverage 2009–2013, Alberta, Canada

BMC Public Health

(2014)

D. Baker et al.

Inequalities in immunisation and breast feeding in an ethnically diverse urban area: cross-sectional study in Manchester, UK

J Epidemiol Community Health

(2011)

K.F. Brown

Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument

Vaccine

(2011)

H.K. Green

Phased introduction of a universal childhood influenza vaccination programme in England: population-level factors predicting variation in national uptake during the first year, 2013/14

Vaccine

(2015)

K.S. Wagner

Childhood vaccination coverage by ethnicity within London between 2006/2007 and 2010/2011

Arch Dis Child

(2014)

R.J. Sacks

Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services

Sex Transm Infect

(2014)

Cited by (17)

Social determinants of health and vaccine uptake during the first wave of the COVID-19 pandemic: A systematic review
2023, Preventive Medicine Reports
Social determinants of health significantly impact population health status. The aim of this systematic review was to examine which social vulnerability factors or determinants of health at the individual or county level affected vaccine uptake within the first phase of the vaccination program. We performed a systematic review of peer-reviewed literature published from January 2020 until September 2021 in Medline and Embase (Bagaria et al., 2022) and complemented the review with an assessment of pre-print literature within the same period. We restricted our criteria to studies performed in the EU/UK/EEA/US that report vaccine uptake in the general population as the primary outcome and included various social determinants of health as explanatory variables. This review provides evidence of significant associations between the early phases of vaccination uptake for SARS-CoV-2 and multiple socioeconomic factors including income, poverty, deprivation, race/ethnicity, education and health insurance. The identified associations should be taken into account to increase vaccine uptake in socially vulnerable groups, and to reduce disparities in uptake, in particular within the context of public health preparedness for future pandemics. While further corroboration is needed to explore the generalizability of these findings across the European setting, these results confirm the need to consider vulnerable groups and social determinants of health in the planning and roll-out of SARS-CoV-2 vaccination programs and within the context of future respiratory pandemics.
Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake
2021, Vaccine
Citation Excerpt :
In the current study, we not only considered influenza and pneumococcal vaccine uptake in the same sample, but also that of the shingles vaccine, which has been investigated to a much lesser extent [4]. Socio-demographic factors have been shown to predict, but not wholly account for, shingles vaccination coverage (i.e. geographical area, level of deprivation, and ethnicity [43]. Although, again, healthcare providers may have a crucial role in shingles vaccine uptake, as key predictors of uptake appear to be awareness of the vaccine and having been offered and recommended it by a healthcare provider [4,24].
Influenza, pneumococcal disease, and shingles (herpes zoster) are more prevalent in older people. These illnesses are preventable via vaccination, but uptake is low and decreasing. Little research has focused on understanding the psychosocial reasons behind older adults’ hesitancy towards different vaccines. A cross-sectional survey with 372 UK-based adults aged 65–92 years (M = 70.5) assessed awareness and uptake of the influenza, pneumococcal, and shingles vaccines. Participants provided health and socio-demographic data and completed two scales measuring the psychosocial factors associated with vaccination behaviour. Self-reported daily functioning, cognitive difficulties, and social support were also assessed. Participants were additionally given the opportunity to provide free text responses outlining up to three main reasons for their vaccination decisions. We found that considerably more participants had received the influenza vaccine in the last 12 months (83.6%), relative to having ever received the pneumococcal (60.2%) and shingles vaccines (58.9%). Participants were more aware of their eligibility for the influenza vaccine, and were more likely to have been offered it. Multivariate logistic regression analyses showed that a lower sense of collective responsibility independently predicted lack of uptake of all three vaccines. Greater calculation of disease and vaccination risk, and preference for natural immunity, also predicted not getting the influenza vaccine. For both the pneumococcal and shingles vaccines, concerns about profiteering further predicted lack of uptake. Analysis of the qualitative responses highlighted that participants vaccinated to protect their own health and that of others. Our findings suggest that interventions targeted towards older adults would benefit from being vaccine-specific and that they should emphasise disease risks and vaccine benefits for the individual, as well as the benefits of vaccination for the wider community. These findings can help inform intervention development aimed at increasing vaccination uptake in future.
Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program
2020, Vaccine
Citation Excerpt :
This pattern has also been observed in the AIR report [10] and for pneumococcal vaccine uptake [24]. We also found patients living in the most socio-economically disadvantaged areas were less likely to receive HZ vaccines; this has been previously reported in the UK [28] and the USA [26]. HZ vaccines have been introduced in other countries, including the US and the UK.
In Australia, a herpes zoster (HZ) vaccination program targeting adults aged 70 years old with catch-up for those 71-79 years began in November 2016 but there is limited information on vaccine uptake and coverage achieved since commencement.
We used a national de-identified electronic primary care dataset, MedicineInsight, and extracted records from patients turning 50–90 years old during 2016–2018. Among patients considered regular attenders, with at least one visit per year in the two years prior, we estimated the crude and adjusted average monthly HZ vaccine uptake in the target population (70–79 years old) for each year since program implementation as well as cumulative vaccine coverage until December 2018. Multivariate logistic regression was used to analyse characteristics associated with higher coverage.
Among 52,229, 55,034, and 57,316 regular attenders turning 70–79 years old in 2016, 2017 and 2018 respectively, the average monthly vaccine uptake rate was 5.5%, 3.3%, and 1.6% respectively. Up to 31st December 2018, the estimated cumulative vaccine coverage in regularly attending adults was 46.9% (25,791/55,034). It was substantially lower at 41.6% (27,040/65,010) using an alternate definition of a regular attender. Vaccine coverage differed by sex (women: 48.5% versus men: 45.1%, adjusted OR = 1.1, 95% CI: 1.1–1.2); by jurisdiction (compared to New South Wales: 43.7%, South Australia: 55.6%, aOR = 1.6, 95% CI (1.5–1.8); Northern Territory: 27.6%, aOR = 0.6, (0.5–0.7)); by remoteness status (compared to major cities: 47.6%, remote/very remote areas: 38.2%, aOR = 0.7, (0.6–0.8)); and by socioeconomic disadvantage (compared to most disadvantaged: 41.8%, most advantaged: 48.6%, aOR = 1.6 (1.2–2.1)).
Our estimates of HZ vaccine coverage are substantially higher than the only other reports based on the Australian Immunisation Register however they still suggest that uptake is suboptimal. The use of electronic medical records can complement other data for estimating vaccine coverage in Australian adults.
Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study
2018, The Lancet Public Health
Citation Excerpt :
Cumulative uptake data indicate most vaccines were delivered during the influenza season, although the vaccine is offered opportunistically throughout the year. Uptake in the participating practices showed geographical variation, similar to that observed nationally, with ethnicity and deprivation identified as contributing factors.14 Uptake was lower than for seasonal influenza vaccination in adults aged 65 years and older, at 73·2% for the 2013–14 season, 72·7% for the 2014–15 season, and 71·0% for the 2015–16 season.15
In 2013, a herpes zoster vaccination programme was introduced in England for adults aged 70 years with a phased catch-up programme for those aged 71–79 years. We aimed to evaluate the effect of the first 3 years of the vaccination programme on incidence of herpes zoster and postherpetic neuralgia in this population.
In this population-based study, we extracted data from the Royal College of General Practitioners sentinel primary care network on consultations with patients aged 60–89 years for herpes zoster and postherpetic neuralgia occurring between Oct 1, 2005, and Sept 30, 2016, obtaining data from 164 practices. We identified individual data on herpes zoster vaccinations administered and consultations for herpes zoster and postherpetic neuralgia, and aggregated these data to estimate vaccine coverage and incidence of herpes zoster and postherpetic neuralgia consultations. We defined age cohorts to identify participants targeted in each year of the programme, and as part of the routine or catch-up programme. We modelled incidence according to age, region, gender, time period, and vaccine eligibility using multivariable Poisson regression with an offset for person-years.
Our analysis included 3·36 million person-years of data, corresponding to an average of 310 001 patients aged 60–89 years who were registered at an RCGP practice each year. By Aug 31, 2016, uptake of the vaccine varied between 58% for the recently targeted cohorts and 72% for the first routine cohort. Across the first 3 years of vaccination for the three routine cohorts, incidence of herpes zoster fell by 35% (incidence rate ratio 0·65 [95% 0·60–0·72]) and of postherpetic neuralgia fell by 50% (0·50 [0·38–0·67]). The equivalent reduction for the four catch-up cohorts was 33% for herpes zoster (incidence rate ratio 0·67 [0·61–0·74]) and 38% for postherpetic neuralgia (0·62 [0·50–0·79]). These reductions are consistent with a vaccine effectiveness of about 62% against herpes zoster and 70–88% against postherpetic neuralgia.
The herpes zoster vaccination programme in England has had a population impact equivalent to about 17 000 fewer episodes of herpes zoster and 3300 fewer episodes of postherpetic neuralgia among 5·5 million eligible individuals in the first 3 years of the programme. Communication of the public health impact of this programme will be important to reverse the recent trend of declining vaccine coverage.
Public Health England.
Extracting general practice data for timely vaccine coverage estimates: The England experience
2017, Vaccine
Citation Excerpt :
Extraction details are available in the data specifications [11]. ImmForm also allows stratification of vaccine coverage by any variable recorded, such as age (by date of birth), ethnicity, gender, specific co-morbidities (e.g. chronic heart disease, diabetes) [12] and place of administration (practice, school, pharmacy etc). The specifications and outputs are internally and externally validated and quality assured to ensure the coverage reported is accurate.
In England, primary care providers use standardised coding systems to record health events such as vaccination as well as patient characteristics. This information can be automatically extracted to estimate coverage for vaccine programmes delivered through primary care, in the general population as well as in specific geographical, ethnic, age or clinical groups. This system provides timely vaccine coverage estimates as well as the flexibility to extract tailored data in order to directly inform a continuously evolving national vaccine programme. It is however limited by the quality and completeness of clinical coding in primary care. A centralised, individual-level register would however improve data quality, completeness and reliability and remains the gold standard.
Forecasting sub-national trends in COVID-19 vaccine uptake in the UK before vaccine rollout
2022, Scientific Reports

View all citing articles on Scopus

View full text

Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15

Highlights

Abstract

Introduction

Methods

Results

Conclusions

Introduction

Section snippets

Data collection

Participation

Sample representativeness and overall coverage

Main findings

Conclusions

Funding

Conflicts of interest

Contributions

Acknowledgements

Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study

BMC Infect Dis

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales

Vaccine

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

Epidemiol Infect

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

N Engl J Med

The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population

Eur J Pain

Modelling the impact of immunization on the epidemiology of varicella zoster virus

Epidemiol Infect

Epidemiology, outcome and control of varicella-zoster infection

Rev Med Microbiol

A systematic review and meta-analysis of risk factors for postherpetic neuralgia

Pain

Risk factors for postherpetic neuralgia in patients with herpes zoster

Neurology

Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease

Jama

Statement on varicella and herpes zoster vaccines

Trends and disparity in zoster vaccine uptake in a managed care population

Vaccine

Herpes zoster vaccine (HZV): utilization and coverage 2009–2013, Alberta, Canada

BMC Public Health

Inequalities in immunisation and breast feeding in an ethnically diverse urban area: cross-sectional study in Manchester, UK

J Epidemiol Community Health

Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument

Vaccine

Phased introduction of a universal childhood influenza vaccination programme in England: population-level factors predicting variation in national uptake during the first year, 2013/14

Vaccine

Childhood vaccination coverage by ethnicity within London between 2006/2007 and 2010/2011

Arch Dis Child

Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services

Sex Transm Infect